Ximelagatran v placebo for secondary prevention of venous thromboembolism (VTE) at 18 months*
| Outcomes | Ximelagatran | Placebo | RRR (95% CI) | NNT (CI) |
|---|---|---|---|---|
| *Abbreviations defined in glossary; RRR, RRI, NNT, NNH, and CI calculated using Cox proportional hazards ratio in article. | ||||
| VTE | 2.8% | 12.6% | 83% (69 to 90) | 10 (9 to 12) |
| All cause mortality | 1.1% | 1.4% | 17% (−143 to 72) | Not significant |
| Major bleeding | 1.1% | 1.3% | 16% (−65 to 273) | Not significant |
| RRI (CI) | NNH | |||
| Major and minor bleeding | 23.9% | 21.0% | 16% (−6 to 44) | Not significant |